GGrantIndex
← Leaderboards

Huiping Rose Zhou

Va Veterans Administration Hospital

$7,173,248
Attributed
$10,982,917
Total exposure
16
Grants
15
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY200625
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,982,917 · 9
VA$0 · 7

By mechanism

R01$9,542,595 · 6
R21$810,740 · 2
R56$629,582 · 1
I01$0 · 4
IK6$0 · 1
IS1$0 · 2

Top collaborators

Others in their field

Top investigators on “Play

Research focus

PlayMolecularBaseReportingBile AcidsLinkMediatingLiver DiseasesHepaticProteinsHepatocyteSignal PathwayLipidsLiver InjuryInflammationSignal TransductionHomeostasisPathogenesisLipid MetabolismLiverNovel TherapeuticsMouse ModelFunctional DisorderGenes

Grant awards (49)

Circular RNAs in Cholestatic Liver Diseases$561,785
R01 · FY2025 · DK · contact PI
Sphingolipids in alcoholic liver disease$523,062
R01 · FY2025 · AA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Bile Acids and Sphingosine 1-Phosphate in Non-Alcoholic Steatohepatitis (NASH)$0
I01 · FY2025 · VA · contact PI
Pathogenic Mechanism for Lung Infection in Mucoid Pseudomonas$0
I01 · FY2025 · VA · contact PI
Circular RNAs in Cholestatic Liver Diseases$561,785
R01 · FY2024 · DK · contact PI
Sphingolipids in alcoholic liver disease$523,062
R01 · FY2024 · AA · contact PI
Bile Acids and Sphingosine 1-Phosphate in Non-Alcoholic Steatohepatitis (NASH)$0
I01 · FY2024 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Pathogenic Mechanism for Lung Infection in Mucoid Pseudomonas$0
I01 · FY2024 · VA · contact PI
LncRNA H19 in Cholestatic Liver Diseases$629,582
R56 · FY2023 · DK · contact PI
Sphingolipids in alcoholic liver disease$523,062
R01 · FY2023 · AA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2023 · VA · contact PI
Bile Acids and Sphingosine 1-Phosphate in Non-Alcoholic Steatohepatitis (NASH)$0
I01 · FY2023 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2022 · VA · contact PI
LncRNA H19 in Cholestatic Liver Diseases$536,469
R01 · FY2021 · DK · contact PI
The ShEEP request for NanoString GeoMx Digital Spatial Profiling and nCounter MAX Complete System$0
IS1 · FY2021 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2021 · VA · contact PI
Mechanisms of Berberine for the Treatment of Non-Alcoholic Fatty Liver Disease$0
I01 · FY2021 · VA · contact PI
LncRNA H19 in Cholestatic Liver Diseases$536,469
R01 · FY2020 · DK · contact PI
Bile Acid and Sphingosine-1-phosphate Receptor-mediated Signaling in Cholestasis$399,609
R01 · FY2020 · DK · contact PI
Sphingosine-1 phosphate signaling in alcoholic liver disease$184,359
R21 · FY2020 · AA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2020 · VA · contact PI
Mechanisms of Berberine for the Treatment of Non-Alcoholic Fatty Liver Disease$0
I01 · FY2020 · VA · contact PI
LncRNA H19 in Cholestatic Liver Diseases$536,469
R01 · FY2019 · DK · contact PI
Bile Acid and Sphingosine-1-phosphate Receptor-mediated Signaling in Cholestasis$393,548
R01 · FY2019 · DK · contact PI
Sphingosine-1 phosphate signaling in alcoholic liver disease$223,112
R21 · FY2019 · AA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2019 · VA · contact PI
Mechanisms of Berberine for the Treatment of Non-Alcoholic Fatty Liver Disease$0
I01 · FY2019 · VA · contact PI
The ShEEP request for Waters Xevo TQ-XS Liquid Chromatography Mass Spectrometer System$0
IS1 · FY2019 · VA · contact PI
LncRNA H19 in Cholestatic Liver Diseases$535,606
R01 · FY2018 · DK · contact PI
Bile Acid and Sphingosine-1-phosphate Receptor-mediated Signaling in Cholestasis$390,905
R01 · FY2018 · DK · contact PI
Mechanisms of Berberine for the Treatment of Non-Alcoholic Fatty Liver Disease$0
I01 · FY2018 · VA · contact PI
Bile Acid and Sphingosine-1-phosphate Receptor-mediated Signaling in Cholestasis$390,481
R01 · FY2017 · DK · contact PI
Bile Acid and Sphingosine-1-phosphate Receptor-mediated Signaling in Cholestasis$411,742
R01 · FY2016 · DK · contact PI
Regulation of Hepatic SphK2 by Bile Acids: Effects on Lipid Metabolism$325,163
R01 · FY2015 · DK
Impact of Alcohol on HIV Protease Inhibitor-induced ER Stress and Lipotoxicity$0
I01 · FY2015 · VA · contact PI
Regulation of Hepatic SphK2 by Bile Acids: Effects on Lipid Metabolism$325,163
R01 · FY2014 · DK
Impact of Alcohol on HIV Protease Inhibitor-induced ER Stress and Lipotoxicity$0
I01 · FY2014 · VA · contact PI
Regulation of Hepatic SphK2 by Bile Acids: Effects on Lipid Metabolism$313,783
R01 · FY2013 · DK
Impact of Alcohol on HIV Protease Inhibitor-induced ER Stress and Lipotoxicity$0
I01 · FY2013 · VA · contact PI
Regulation of Hepatic SphK2 by Bile Acids: Effects on Lipid Metabolism$325,163
R01 · FY2012 · DK
Impact of Alcohol on HIV Protease Inhibitor-induced ER Stress and Lipotoxicity$0
I01 · FY2012 · VA · contact PI
Prevent HIV protease inhibitor-induced atherosclerosis by Berberine$355,517
R01 · FY2010 · AT · contact PI
Prevent HIV protease inhibitor-induced atherosclerosis by Berberine$359,336
R01 · FY2009 · AT · contact PI
Prevent HIV protease inhibitor-induced atherosclerosis by Berberine$359,556
R01 · FY2008 · AT · contact PI
Prevent HIV protease inhibitor-induced atherosclerosis by Berberine$354,860
R01 · FY2007 · AT · contact PI
HIV Protease Inhibitors, the Unfolded Protein Response and Atherosclerosis$217,019
R21 · FY2007 · AI · contact PI
HIV Protease Inhibitors, the Unfolded Protein Response and Atherosclerosis$186,250
R21 · FY2006 · AI · contact PI